MedTrace Logo

Effect of Platelet Inhibition According to Clopidogrel Dose in Patients With Body Mass Index ≥ 27

NCT01509365 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 116

Last updated 2015-05-07

No results posted yet for this study

Summary

The purpose of the study is to determine whether administration of 150 mg clopidogrel is effective in reducing the one-year incidence of thromboischemic events in patients with high on-clopidogrel platelet reactivity compared to 75 mg clopidogrel in the patient population overweight or obese with a body mass index (BMI) ≥ 27 kg.m-2.

Conditions

Interventions

DRUG

clopidogrel

2 tablets of 75 mg clopidogrel for one month followed by standard 75 mg clopidogrel for 3 months to one year.

DRUG

clopidogrel

1 tablet of 75 mg clopidogrel for one month followed by standard 75 mg clopidogrel for 3 months to one year.

Sponsors & Collaborators

  • University Hospital Fattouma Bourguiba

    collaborator OTHER

  • Les Laboratoires des Médicaments Stériles

    lead INDUSTRY

Principal Investigators

  • Faouzi Maatouk, MD · hospital Fattouma Bourguiba

  • Khaldoun Ben Hamda, MD · Hospital Fattouma Bourguiba

  • Sonia Hamdi, MD · Hospital Fattouma Bourguiba

  • Mohsen Hassine · Hospital Fattouma Bourguiba

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-12-31
Primary Completion
2015-02-28
Completion
2015-05-31

Countries

  • Tunisia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01509365 on ClinicalTrials.gov